171 results
8-K
EX-99.1
ARAV
Aravive Inc
17 Jan 24
Entry into a Material Definitive Agreement
4:22pm
-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can
8-K
EX-10.1
ARAV
Aravive Inc
17 Jan 24
Entry into a Material Definitive Agreement
4:22pm
investigation, litigation or proceeding related to or arising out of any of the foregoing, whether or not any Indemnified Person is a party thereto
8-K
o51vy2t8d2zf yz4c28
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
8-K
EX-99.1
46by29usy r4mh
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
8-K
k6ln8ns6xpgfe zplx
5 Jun 23
Regulation FD Disclosure
4:05pm
8-K
mu40jg59gwok
25 May 23
Regulation FD Disclosure
5:00pm
8-K
EX-99.1
vfm9w4stwrgk3 ib29
25 May 23
Regulation FD Disclosure
5:00pm
8-K
qfy2l1 k9s9uaddj6
16 May 23
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
c3m 5d9waugy7tn
16 May 23
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
ba9i0l
10 May 23
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
4:05pm
8-K
EX-99.1
c4bg2oz9mzz3qy9rw
11 Apr 23
Aravive Appoints Carolina Petrini as Chief Commercial Officer
7:10am
8-K
mh4sco
29 Nov 22
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
7:05am
8-K
EX-99.1
a7fm70g my696
29 Nov 22
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
7:05am